CIRM Funded Clinical Trials

Evaluation of the Safety and Tolerability of KA34 in a Phase 1, Double-Blind, Dose Escalation Trial in Patients with Knee Osteoarthritis


Disease Area:
Arthritis, Osteoarthritis
Investigator:
Dr. Kristen A Johnson
Institution:
Calibr
CIRM Grant:
CLIN2-10388 (Closed)
Award Value:
$8,447,523.00
Trial Sponsor:
Calibr
Trial Stage:
Phase 1
Trial Status:
Completed
Targeted Enrollment:
60
ClinicalTrials.gov ID:
NCT03133676

Details:

Researchers at the California Institute for Biomedical Research (CALIBR) have been awarded $8.447 million to test KA34, a drug that, in preclinical tests, recruits stem cells to create new cartilage in areas damaged by osteoarthritis. CIRM funded the research that developed this technology and now this Phase 1 trial will test this stem cell directed treatment in people with osteoarthritis of the knee, hopefully slowing down or even halting the progression of the disease. 

Design:

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study.

Goal:

This study will evaluate the safety and tolerability of KA34 when administered to patients with osteoarthritis of the knee.

Updates:

Podcast - Dr. Kristen Johnson & Dr. Maria Millan: Regenerative Medicine for Osteoarthritis

Contact Trial Sponsor

CIRM Clinical Trial Resources

Patient Stories of Hope

CIRM Alpha Stem Cell Clinics

Patient Toolbox

Video on Stem Cell Trials

Other Resources

ISSCR Patient Website

ClinicalTrials.gov